Literature DB >> 17881630

Antimicrobials for right-sided endocarditis in intravenous drug users: a systematic review.

Derek Yung1, Dan Kottachchi, Binod Neupane, Shariq Haider, Mark Loeb.   

Abstract

BACKGROUND: Right-sided endocarditis (RSE) is a serious complication of intravenous drug use. We sought to systematically review the evidence for obtaining clinical cure with antimicrobials in intravenous drug users (IVDUs) with isolated native valve RSE. SEARCH STRATEGY: We applied broad search strategies in the following databases: MEDLINE (1966-2006), EMBASE (1980-2006) and Cochrane CENTRAL Register (2006, Issue 3). Hand searching was performed on selected peer-reviewed journals and relevant citation lists were screened. No restrictions were set on language and type of publication. SELECTION CRITERIA: We included randomized controlled trials that evaluated clinical and microbiological cure using single or combination antibiotic regimens for the treatment of isolated native valve bacterial RSE. Clinical and microbiological cure and failure outcomes were evaluated between 2 weeks and 6 months after completion of therapy. Quality assessment of relevant studies was performed using an objective scoring scale.
RESULTS: We identified seven randomized controlled trials, one comparing single antimicrobial therapies, four comparing combination with single therapy and two studies comparing combination therapies. Short-course therapy was present in at least one arm in three studies, but only one study compared short- and long-course therapy. No statistically significant benefit was demonstrated between any antimicrobial therapy and all studies were scored as having a moderate to severe risk of bias.
CONCLUSIONS: Randomized trial evidence does not support one antimicrobial regimen over another in the treatment of RSE in IVDUs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17881630     DOI: 10.1093/jac/dkm324

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Intravenous drug abuse and tricuspid valve endocarditis: Growing trends in the Middle East Gulf region.

Authors:  Prashanth Panduranga; Seif Al-Abri; Jawad Al-Lawati
Journal:  World J Cardiol       Date:  2013-11-26

2.  A comparison of different antibiotic regimens for the treatment of infective endocarditis.

Authors:  Arturo J Martí-Carvajal; Mark Dayer; Lucieni O Conterno; Alejandro G Gonzalez Garay; Cristina Elena Martí-Amarista
Journal:  Cochrane Database Syst Rev       Date:  2020-05-14

3.  Relapse of polymicrobial endocarditis in an intravenous drug user.

Authors:  Ruth W Wang'ondu; Thomas S Murray
Journal:  Yale J Biol Med       Date:  2011-09

4.  A 34-Year-Old Male Intravenous Drug User with a Third Episode of Tricuspid Valve Endocarditis Treated with Repeat Valve Surgery.

Authors:  Jeffrey W Cannon; J W Awori Hayanga; Thomas B Drvar; Matthew Ellison; Christopher Cook; Muhammad Salman; Harold Roberts; Vinay Badhwar; Heather K Hayanga
Journal:  Am J Case Rep       Date:  2021-03-29

5.  Comparative effectiveness of β-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia.

Authors:  Davie Wong; Titus Wong; Marc Romney; Victor Leung
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-04-26       Impact factor: 3.944

6.  Comparison of outcomes in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia who are treated with β-lactam vs vancomycin empiric therapy: a retrospective cohort study.

Authors:  Davie Wong; Titus Wong; Marc Romney; Victor Leung
Journal:  BMC Infect Dis       Date:  2016-05-23       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.